PMC:7029759 / 1585-1780 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"29","span":{"begin":4,"end":8},"obj":"Gene"},{"id":"30","span":{"begin":52,"end":56},"obj":"Gene"},{"id":"47","span":{"begin":84,"end":93},"obj":"Disease"},{"id":"48","span":{"begin":121,"end":147},"obj":"Disease"}],"attributes":[{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"Gene:59272"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"Gene:59272"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D007239"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D012128"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The ACE2-Fc therapy would also supplement decreased ACE2 levels in the lungs during infection, thereby directly treating acute respiratory distress pathophysiology as a third mechanism of action."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T8","span":{"begin":4,"end":8},"obj":"G_3;PG_10;PR:000003622"},{"id":"T7","span":{"begin":52,"end":56},"obj":"G_3;PG_10;PR:000003622"},{"id":"T6","span":{"begin":71,"end":76},"obj":"UBERON:0000170"},{"id":"T5","span":{"begin":127,"end":138},"obj":"UBERON:0001004"}],"text":"The ACE2-Fc therapy would also supplement decreased ACE2 levels in the lungs during infection, thereby directly treating acute respiratory distress pathophysiology as a third mechanism of action."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":71,"end":76},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma68877"}],"text":"The ACE2-Fc therapy would also supplement decreased ACE2 levels in the lungs during infection, thereby directly treating acute respiratory distress pathophysiology as a third mechanism of action."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T4","span":{"begin":84,"end":93},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The ACE2-Fc therapy would also supplement decreased ACE2 levels in the lungs during infection, thereby directly treating acute respiratory distress pathophysiology as a third mechanism of action."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T15","span":{"begin":9,"end":11},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T16","span":{"begin":71,"end":76},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T17","span":{"begin":167,"end":168},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The ACE2-Fc therapy would also supplement decreased ACE2 levels in the lungs during infection, thereby directly treating acute respiratory distress pathophysiology as a third mechanism of action."}

{"project":"LitCovid-sentences","denotations":[{"id":"T13","span":{"begin":0,"end":195},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The ACE2-Fc therapy would also supplement decreased ACE2 levels in the lungs during infection, thereby directly treating acute respiratory distress pathophysiology as a third mechanism of action."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":127,"end":147},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"The ACE2-Fc therapy would also supplement decreased ACE2 levels in the lungs during infection, thereby directly treating acute respiratory distress pathophysiology as a third mechanism of action."}